Clareo Health | Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Phase 1: Single Arm Study
Phase 2: Randomized Controlled, Parallel
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with K-RAS (codon 12 or 13) or B -RAF (V600E) mutation positive advanced or metastatic colorectal cancer who have relapsed or are refractory to 2 or more standard systemic anticancer regimes for metastatic disease, or are intolerant to existing therapies.
Histologic or cytologic confirmation of the diagnosis.
Eastern Cooperative Oncology Group (ECOG) ≤ 1
Adequate organ \& marrow function.
You may not be if
Uncontrolled or significant cardiovascular disease.
